Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.71, $0.22 better than the analyst estimate of $0.49. Revenue for the quarter came in at $222.2 million versus the consensus estimate of $279 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.